Next Investors logo grey

Alcidion re-signs Western Sussex Hospitals Trust


Published 26-JUN-2019 09:43 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Alcidion Group Ltd (ASX:ALC) has signed a 5-year product licence renewal agreement with Western Sussex Hospitals NHS Trust for Patientrack licensing and support for an additional five years, to 2024.

The total value of the renewal is $970,000.

Contract successes such as this have been responsible for shares in the group trading strongly since March, increasing 370% to hit a 12 month high of 14 cents in June.

Alcidion’s Patientrack platform is a mobile and digital bedside solution that helps hospitals improve patient safety and quality of care, as well as optimising clinical staff efficiency.

Patientrack helps hospital workflow by planning and performing patient observations and assessments and providing clinical documentation at the bedside in real-time.

These functions of the Patientrack solution ensure the early detection and timely clinical response to deteriorating patients at all times, in a range of different ward environments.

Contract renewals are viewed as an endorsement

One of the important aspects of this contract win is that Western Sussex Hospitals NHS Trust first implemented Patientrack in 2012, making it one of the longest-serving users of the software.

It is endorsements such as this that will provide investors with confidence regarding further contract extensions, and it is worth noting that it is the second time the contract has been renewed.

The platform was initially deployed following a successful competitive tender in 2011, and the system is live in 68 wards across the trust’s three hospitals.

Alcidion’s group managing director Kate Quirke underlined the importance of the trust’s endorsement of the company’s products in saying, “We are delighted to continue our close partnership with Western Sussex Hospitals NHS Trust - one of our foundation customers in the UK - for the continued use of Patientrack for another five years.

“This demonstrates the longevity of our relationships with customers who have embedded Patientrack into their clinical care.”

Patientrack being used in a clinical care environment.

Aligning tech innovation with industry developments

Alcidion’s UK general manager Donald Kennedy explained the importance of staying abreast of new healthcare developments in saying, “Our long-standing partnership with Western Sussex NHS Trust has seen several innovations made to Patientrack, and its use has expanded within the trust since it was implemented.

“These include the implementation of world-leading predictive analytics for acute kidney injury, as well as a broad range of clinical assessments and workflow for conditions such as Sepsis.

“This renewal demonstrates the benefits our solutions can bring to patients and health professionals, and the value our solutions can add to wards, hospitals and healthcare systems.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.